Status:
NOT_YET_RECRUITING
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
Lead Sponsor:
AstraZeneca
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
Brief Summary
Systemic lupus erythematosus (SLE) is an autoimmune condition characterized by a complicated, unclear etiology that involves various complex factors. SLE symptoms and indications are broadly classifie...
Eligibility Criteria
Inclusion
- Adults of both genders aged 18 or older at the time of study inclusion.
- Patients with medical records from the selected sites between 2016 and 2023 with at least one year of follow-up records.
- Patients receiving routine treatment in the participating sites.
- Patients with an SLE diagnosis.
- Due to the retrospective nature of the study a waiver grant of the consent will be requested from the IRB/IEC for the study participants, if waiver not granted Patient or next of kin/legal representative (for deceased patients at study entry) willing and able to provide written informed consent according to the local regulations.
Exclusion
- Patients with new-onset SLE as they will have insufficient data.
- Patients whose records have insufficient data (for example, due to lost follow up).
Key Trial Info
Start Date :
August 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT07144514
Start Date
August 31 2025
End Date
December 31 2025
Last Update
August 27 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.